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Abstract
High grade malignant gliomas are among the most radioresistant human tumors and total doses up to 80 Gy are inadequate 
to achieve long-term local control in most of the patients. Hypoxia has been demonstrated in primary brain tumors and may be 
one of the reasons for their radioresistance. In experimental models carbogen breathing and nicotinamide have been shown to act 
against hypoxia by different mechanisms and both modalities were tested in 16 patients with supratentorial malignant gliomas in 
combination with a conventional radiotherapy scheme (50 Gy in 25 daily fractions). The present study was performed to determine 
the feasibility and toxicity of conventional radiotherapy combined with carbogen breathing and nicotinamide. The unexpectedly 
high incidence of acute liver toxicity, the possible increase of subacute and late CNS toxicity, and the absence of a higher effectivity 
led us to reconsider this new treatment modality for patients with malignant gliomas.
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1. Introduction
The disappointing results o f current treatment moda­
lities for patients with malignant gliomas necessitate the 
search for new treatment approaches. The standard 
therapy for high grade malignant gliomas consists of  
surgery and postoperative radiotherapy. Although radi­
otherapy significantly prolongs survival, the absolute 
survival benefit is only modest. Local recurrence is 
almost always the cause o f failure and several factors 
such as intrinsic radiosensitivity, tumor cell kinetics, and 
hypoxia are thought to be the underlying reasons. A
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relatively high intrinsic radioresistance of human brain 
tumors has been reported by Fertil and Malaise after 
determining a, the mean inactivation dose, and the sur­
viving fraction after 2 Gy (SF2) in vitro [3]. Others, 
however, have found a wide range of SF2-values and 
postulate that not only the high intrinsic radioresistance 
of high grade malignant gliomas but also other factors 
determine their incurability by radiation therapy [19], 
One of the other factors might be the high proliferative 
capacity of malignant gliomas [10]. Because o f these 
tumor characteristics, in some radiotherapy schemes the 
tumor dose was increased and overall treatment time 
shortened. Hyperfractionation up to total doses of 80 
Gy in 5.5 weeks (three fractions o f -  1 Gy per day) [5]
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and accelerated fractionation to 60 Gy in 2 weeks (three 
fractions of 1.6 Gy per day) [13], however, have not led 
to improved survival. Extrinsic factors such as the 
presence of hypoxia may further compromise the 
radiosensitivity o f the clonogenic tumor cell compart­
ment. The presence of hypoxic cells in human malignant 
gliomas has been demonstrated in vivo [12,16]. There is 
some clinical evidence that these hypoxic tumor cells can 
be sensitized by metronidazole [20]; although subse­
quent studies with metronidazole and other hypoxic cell 
radiosensitizers showed no positive effect on survival 
when combined with standard dose radiotherapy. Of all 
clinical studies with the objective to reduce the hypoxic 
tumor cell compartment in malignant gliomas there is 
no evidence that the measures taken to reduce the hy­
poxia really had the desired effect.
This paper deals with the acute toxicity and treatment 
results of conventional radiotherapy combined with car- 
bogen breathing and nicotinamide.
2. Patients and methods
Sixteen consecutive patients with histologically pro­
ven malignant supratentorial astrocytic neoplasms, who 
fulfilled the inclusion criteria (age between 18 and 70 
years; WHO performance status of 0-3; no severe heart 
or lung disease; no severe liver or kidney function distur­
bances; written informed consent), were entered into the 
study over the period November 1992 to January 1994. 
The extent of neurosurgical intervention ranged from bi­
opsy only to macroscopically total resection. Detailed 
information about each individual patient is summariz­
ed in Table 1. In this series there was only one patient 
(No. 2) with a macroscopically total resection.
After neurosurgery, but before the start of radiother­
apy MRI-scans, with and without gadolinium-DTPA, 
were made to determine the result of the surgical proce­
dure and the tumor extension at the start of radio­
therapy. The target volume consisted of the contrast 
enhancing region with a 2-cm margin. Patients were
treated with megavoltage equipment (4 or 6 MV) by 
weighted parallel opposing beams. In an overall treat­
ment time of 5 weeks a total dose of 50 Gy was ad­
ministered in 25 daily factions of 2 Gy. There was no 
reduction of the target volume during the treatment 
period. Radiotherapy was combined with carbogen 
breathing by the method presented earlier [11]. Car­
bogen breathing started 5 min before irradiation and 
was continued during treatment. Six grams of nicotin­
amide dissolved in orange squash were ingested 1.5 h 
before each treatment. Actual plasma and tissue concen­
trations of nicotinamide were not measured, but others 
have shown that a mean peak level of 159.5 fig/ml could 
be measured in healthy volunteers 45 min after ingestion 
of 6 g nicotinamide [9]. It is expected that the plasma 
level will stay above 100 /xg/ml for 1-2  h after reaching
Table 1
Patient characteristics
y
No. Gender Age Hist. EO WHO
1 M 64 4 PR 1
2 F 55 4 TR 1
3 M 52 4 PR I
4 M 45 3 BI 1
5 M 64 4 BI 3
6 M 48 4 PR I
7 M 51 4 PR 1
8 M 48 4 PR 1
9 F 51 3 BI 1
10 M 55 4 BI 3
11 M 60 4 PR 3
12 M 59 4 PR 1
13 F 61 4 PR 2
14 M 63 4 PR 1
15 M 47 4 PR 1
16 F 46 4 PR 1
Patient number, gender, age at the time of diagnosis, histologic grade 
according to Daumas-Duport [2], extent of operation (EO) (TR, total
resection; PR, partial resection; BI, biopsy), and performance status 
according to WHO at the start of radiotherapy.
its peak. Animal data  suggest that such a level will be 
sufficient for substantial radiosensitization.
The effect of the treatm ent on tum or and normal CNS 
was evaluated with M R I scans at 1 and 3 m onths after 
completion of treatm ent and every 3 m onths thereafter. 
In one patient with claustrophobia evaluation was per­
formed by CT-scans.
This clinical study has been approved by the local 
ethical committee and informed written consent was 
given by all patients before treatment.
3. Results
3.L Acute effects
3.1.1. Liver toxicity 
In four o f the 16 patients (Nos. 2, 4, 5 and 13) there 
was a clear relationship between nicotinamide medica­
tion and serum liver enzyme disturbances. In two of 
these four patients (Nos. 2 and 13) nicotinamide led to 
severe nausea and vomiting which necessitated hospital­
ization in the first and second week o f  treatment, respec­
tively. The clinical symptoms were accompanied by 
hepatic toxicity reflected in elevated liver serum enzymes 
(LDH, ASAT, A LAT) (Figs. 1, 2). The clinical symp­
toms and liver enzyme disturbances disappeared within 
a few days after stopping nicotinamide medication. 
Another patient (No. 5) started treatm ent with already 
some elevated liver serum enzymes which worsened after 
moderate doses (1.5 and 3 g) o f nicotinamide. N euro­
logical deterioration in the 4th week o f treatm ent led to 
abolishing the intake o f  nicotinamide. In the fourth pa­
tient (No. 4) the nicotinamide-related liver enzyme dis-
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Figs. 1, 2. Two patients with severe acute hepatic toxicity due to nicotinamide. The upper panels show the changes in serum liver enzymes in relation 
to medication (bottom panels). The first patient (No. 2) used Tegretol® (carbamazepine; 3 x 100 mg) in combination with nicotinamide. Three 
administrations of 6 g of nicotinamide caused severe clinical symptoms and liver toxicity. The second patient (No. 13) used Atrovent® (ipratropium- 
bromide; 2 -4  x 250 /ig) and Seresta® (oxazepam; 3 X  25 mg) together with nicotinamide. In the second week of treatment (after 8 X  6 g 
nicotinamide) toxicity became apparent.
turbances were only moderate and he was able to 
complete the planned treatment. The high frequency of 
liver enzyme disturbances may be due to concomitant 
medication with known liver toxicity such as cor­
ticosteroids (Nos. 4 and 5); benzodiazepines (Nos. 5 and 
13) or anti-epileptics (Nos. 2 and 4).
5.7.2. Psychiatric disorders 
Two of the 16 patients (Nos. 8 and 16) showed 
psychiatric symptoms during treatment. The first pa­
tient experienced paranoia and visual hallucinations 
after 4 weeks of therapy. These symptoms disappeared 
after the administration of anti-psychotic medication 
and the patient was able to complete the treatment. In 
the second patient paranoia and auditory hallucinations
occurred during the second week of treatment. Because 
of the severity of the symptoms and their unclear etiol­
ogy it was decided to stop carbogen breathing and 
nicotinamide. Within 3 days the symptoms disappeared 
and radiation treatment was completed without further
complications. In the week following treatment, how­
ever, the patient experienced a relapse into paranoia and 
hallucinations and needed anti-psychotic medication.
Whether nicotinamide and carbogen breathing in­
duces or sensitizes patients with brain tumors to the de­
velopment of psychotic symptoms remains unclear.
3.1.3. Carbogen breathing
Carbogen breathing according to the method describ­
ed by Kaanders and Van der Maazen [11] is tolerated
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well by most patients. The high content of carbondiox- 
ide causes an increased breathing rate after 2 -3  min but 
most patients were able to continue carbogen breathing 
for 10-15 min. Carbogen breathing was stopped in two 
patients (Nos. 5 and 12) in the fifth week of treatment 
because of neurological deterioration and in one patient 
(No. 16) because of psychotic symptoms in the third 
week of treatment.
3.2. Subacute and late effects
Because long-term survival is rare for patients with 
malignant gliomas, only limited information is available 
on the subacute and late toxicity. Corticosteroid medi­
cation may be a measure for radiation-induced edema 
and the need for continued corticosteroid medication 
after completion of treatment may reflect toxicity, 
although tumor progression may also be the underlying 
reason. In this patient group only two patients were able 
to discontinue the corticosteroid medication. All other 
patients experienced an increase of neurological symp­
toms when steroids were decreased or stopped.
In three patients (Nos. 6, 9 and 12) evaluation of the 
treatment with MRI-scans showed an increase of edema 
without signs of tumor progression. Despite high doses 
of corticosteroids two of these patients (Nos, 6 and 12) 
died rapidly and no additional scans could be made. In 
the third patient (No. 9) a remarkable effect of cor­
ticosteroid medication was noticed. At 3 months after 
finishing therapy she experienced an epileptic attack and 
a deterioration of her neurological status. Until then she 
had not used corticosteroid medication. The MRI-scan 
showed severe edema with a shift of the midline struc­
tures. After corticosteroid therapy a considerable reduc­
tion of the midline shift was noted on the MRI-scan 
reflected in a great improvement of the clinical situation. 
Although the good response to corticosteroids might in­
dicate that in this patient the neurological deterioration 
was related to treatment-induced toxicity, a contribu­
tion by tumor progression is difficult to rule out, 
especially since 6 months after the first signs of edema 
progressive tumor growth was evident.
3.3. Tumor responses and survival
MRI-scans were made at 1 and 3 months after com­
pletion of therapy and every 3 months thereafter. One 
patient (No. 13) was evaluated with CT-scans due to 
claustrophobia. In none of the 16 patients was a com­
plete or partial response as defined by the criteria of 
Macdonald et al. [15] noticed.
At the time of the last evaluation (February 1995) 14 
of the 16 patients have died. Two patients are alive at 17 
and 27.5 months after surgery, but both have clinical
and radiological evidence of tumor progression. The 
survival (with a median of 233 days and two patients 
surviving more than 1.4 years) estimated according to 
Kaplan-Meier is comparable with historical controls.
4, Discussion
Hypoxia and (accelerated) proliferation o f  tumor cells 
are factors that negatively influence the outcome of radi­
ation therapy. There is a substantial am ount o f  data that 
indicate that some tum ors are better controlled when ra­
diation therapy is combined with measures that count­
eract either hypoxia or proliferation o f  tum or cells. The 
best clinical examples are probably cervical cancers [8] 
and head and neck tum ors [6,1,4]. A lthough several 
studies indicate that hypoxia and fast proliferation of 
tumor cells are also present in m alignant gliomas 
[12, 10], the contribution o f these factors to the radio­
resistance o f malignant gliomas is unclear. Until now, 
attempts to counteract either hypoxia or fast prolifera­
tion by hypoxic cell sensitizers, hyperbaric oxygen,
hyperfractionation, or accelerated fractionation have 
not led to improvement o f treatm ent results. A combina­
tion of both approaches as described by A R C O N  (accel­
erated radiotherapy combined with carbogen breathing 
and nicotinamide) m ight be m ore promising.
Acceleration of radiation therapy limits the time for 
extensive proliferation o f tum or cells between fractions 
and should result in a higher cure rate in fast pro­
liferating tumors. However, by reducing the overall 
treatment time acute and eventually late normal tissue 
reactions become limiting factors.
Laboratory studies have shown that carbogen breath­
ing and nicotinamide leads to increased therapeutic 
ratios when applied in com bination with fractionated 
radiotherapy. The higher effectiveness o f this combined 
modality treatment is a t least partly due to a reduction 
in the number of hypoxic cells. In experimental tumors 
enhancement ratios o f 1.2 to 2.0 [14,17,18] have been 
obtained. Although increased radiation sensitivity of 
normal tissues was observed, enhancement ratios were 
far less pronounced (dose enhancement factors of 1.1 to 
1.2) resulting in a selective sensitization o f  tumor cells. 
Of the normal tissues, the rat spinal cord seems the most 
affected by the A R C O N  treatment. A decrease in radia­
tion tolerance of ~ 20% was observed when radiation 
was combined with carbogen breathing and nicotina­
mide [7],
Therefore, one may conclude that combination of ac­
celerated radiotherapy with carbogen breathing and 
nicotinamide could lead to a substantial decrease in ra­
diation tolerance o f the normal CNS of up to -40% . 
However, this loss of tolerance may be more than com­
pensated for by the positive results in experimental 
tumors from combined treatm ent with carbogen breath­
ing and nicotinamide, and allows clinical testing in ma­
lignant brain tumors. To reduce the risk of severe 
radiation-induced CNS toxicity, it was decided to com­
bine carbogen breathing and nicotinamide with a con­
ventional radiation scheme with a reduced total dose (50 
Gy instead of 60 Gy). To test the feasibility and toxicity 
16 patients were entered into the study.
An unexpectedly high incidence o f  acute toxicity was
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encountered, most of it could be attributed to nicotin­
amide. Nicotinamide has been clinically applied in many
different diseases and in high daily doses [21]. Although 
transient liver toxicity has been reported, the incidence 
was very low. Therefore, it was surprising that in this 
pilot study of only 16 patients two had severe hepatic 
toxicity. Another two developed psychiatric disorders. 
Whether this was due to the primary brain tumor or to 
the nicotinamide medication is unclear. Patients with 
primary brain tumors may be more susceptible to this 
possible side effect of nicotinamide. A permanent de­
pendence on corticosteroids was noted in 14 of the 16 
patients. This might reflect increased CNS toxicity but 
the poor overall survival due to tum or progression does 
not allow us to draw firm conclusions.
From this study it is also apparent that most of the 
patients were able to breath carbogen for 10-15 min. 
However, when neurological status deteriorates, car­
bogen breathing may become too great a burden. On the • 
basis of these experiences it is advised that carbogen 
breathing should not be attempted in patients with a
performance status worse than W H O  level 2.
This pilot study in which patients with malignant 
supratentorial gliomas were treated with radiation (50 
Gy in 2-Gy daily fractions) in combination with car­
bogen breathing and nicotinamide brings us to the con­
clusion that a higher than expected acute toxicity was 
seen from nicotinamide and that five of 16 patients were 
unable to complete the planned treatment. No benefit of 
survival was found when compared with historical con­
trol studies. The expected increase in late toxicity when 
carbogen breathing and nicotinamide are combined 
with higher doses or accelerated schemes of radiation 
will probably limit the clinical use of carbogen breathing
and nicotinamide in patients with malignant gliomas. 
Some patients, however, might benefit from the propos­
ed treatment modifications. Pre-treatment testing of 
changes in tumor oxygenation and tumor perfusion in 
vivo by means of M RS, SPECT, or PET could select pa­
tients for specific treatment modalities.
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